

Figure 6 ShcC downregulation negatively affects tumorigenicity *in vivo*. (a) Cells transfected with the miR RNAi vector for ShcC (miShcC) and LacZ (miLacZ) that also contains an EmGFP coding sequence for co-cistronic expression with the pre-miRNA were cultured in medium containing blasticidin (Invivogen) for only 1 week, and then mixed. Multiclonal cells for LacZ and ShcC were analysed for the ability of anchorage-independent growth using soft agar assay by 1×10^4 cells per a well of six-well plate for 3 weeks (as described in previous report; Miyake *et al.*, 2005). The results represent the average value (\pm s.d.) of three replicated experiments. (b) Expression levels of ShcC in clones of TNB-1 cells stably transfected with miR RNAi expression vector for LacZ (miLacZ-1 and miLacZ-2) and ShcC (miShcC-1, -2 and -3) were detected by western analysis using α ShcC (as described in 'Materials and methods'). (c) Nude mouse tumors derived from two clones of LacZ miR RNAi and three clones of ShcC. Upper panel: Photographs of tumors from nude mice at 6 weeks after subcutaneous injections of 5×10^6 cloned cells (bar: 20 mm); lower panel: ability of *in vivo* tumorigenicity is shown by average weight (\pm) of four tumor derived from each clone. (d) ShcC-knockdown cells show tendency to apoptosis *in vivo*. Upper panel: Photographs of a cross-section of each tumor tissues from miLacZ-1 and miShcC-2 using microscope at a magnification of $\times 400$, that were stained with hematoxylin and eosin (HE), diaminobenzidine (DAB) by terminal transferase dUTP nick-end labeling (TUNEL) assay and anti-Ki-67 antibody (bar: 25 μ m); lower panel: the tendency to apoptosis was defined as the number of positive stained cells per 1000 tumor cells in TUNEL assay and the proliferating activity was indicated as the labeling index of Ki-67 by counting 1000 tumor cells. The data show the average scores \pm s.d. of positive cells in three different areas of each slide. Staining of each sample was owing to the procedure by SRL Inc.

International Neuroblastoma Staging System and *N-Myc* amplification (> 10 copy) accepted as a poor prognostic risk factor was checked before clinical intervention.

Reagents

The polyclonal antibodies against the CH1 domain of human ShcC (amino acid 225–324): α ShcC were generated by the same method as described previously (Miyake *et al.*, 2002). Polyclonal antibodies of human ShcA: α ShcA were prepared as described in previous reports (Miyake *et al.*, 2002).

Other antibodies were purchased as follows: antiphosphotyrosine antibody (4G10) (Upstate Biotechnology Inc., Charlottesville, VA, USA), anti-ShcA/ShcC monoclonal antibodies: α ShcA/ α ShcC (BD Transduction Laboratories, San Diego, CA, USA), anti- α -tubulin antibody (Zymed Laboratories, San Francisco, CA, USA), anti-p44/42 MAPK (ERK1/2), anti-phospho-p44/42 MAPK (P-ERK1/2), anti-Akt, and anti-phospho-Akt (Ser473) (P-Akt) antibodies (Cell Signaling, Danvers, MA, USA), anti-chromogranin A (ChrA) antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-GAP43 antibody (Zymed Laboratories), anti-MAP2 antibody

(Santa Cruz Biotechnology), anti-c-Src antibody (Upstate Biotechnology Inc.), anti-phospho-Src family antibody (Tyr416) (Cell Signaling), anti-Grb2 antibody (BD Transduction Laboratories), anti-T7tag antibody (Novagen, San Diego, CA, USA) and anti-Flag M2 antibody (Sigma). As secondary antibodies, horseradish peroxidase-conjugated anti-rabbit and anti-mouse IgGs (GE Healthcare, Buckinghamshire, UK) were used. All inhibitors used in this study (PD98059, LY294002, PP2 and PP3) were purchased from Calbiochem, San Diego, CA, USA.

Cell stimulation, immunoprecipitation and immunoblotting

Cell stimulation analysis with EGF (Wako) was performed as described (Miyake *et al.*, 2002). The cells were starved for 24 h and treated for 5 min with EGF (100 ng/ml). As for stimulation with collagen type I, cultured cells with or without serum for 24 h were detached from culture dishes by pipette treatment and after the suspending condition for 30 min, seeded onto a collagen type I-coated dish (Iwaki, Tokyo, Japan). Cells were harvested after 2 h using PLC lysis buffer. Control cells were harvested before the attachment on the collagen I-coated

surface. The immunoprecipitation and western analysis were performed using the procedure described in a previous report (Miyake et al., 2002).

Quantification and statistical analysis of expression levels of ShcC/ShcA

The intensity of each band obtained by western analysis was measured using a molecular imager (GS-800; Bio-Rad, Hercules, CA, USA) and standardized according to control signals, such as the bands of TNB-1 and α -tubulin.

t-Test performed by Excel was used to evaluate the significance of the two groups quantified expression levels of indicated molecules.

Knockdown of ShcA/ShcC by RNA interference

For siRNAs, Stealth RNA duplex oligonucleotides (Invitrogen, Carlsbad, CA, USA) was used to knockdown ShcC/ShcA protein. The following two 25-mer oligonucleotide pairs for each molecule were available. As for ShcC, CR1: 5'-GCUGGCCAAAGCGCUCUAGACAAU-3' (nucleotides 141-165), CR2: 5'-CCAAGAUUUUGGGCGCAGCAA-3' (nucleotides 2447-2471). As negative controls for each oligonucleotide pair, cc1: GGCUCAGAACGGCCUUAGU AACAU-3', cc2: GGAAACCGACAACUACGAUGUCAAU, respectively. As for ShcA, AR1: 5'-GGAGUAACCGAA AUUUGCGUGAAU-3' (nucleotides 335-359). AR2: 5'-GCCU UCGAGUUGCGCUCAAACAAU-3' (nucleotides 689-711). As a negative control for each, ac1: GGAAACCGUAAUUAU CCGUGUGAA, ac2: 5'-UGCCGCGAUUCGCGUUACAAC UAAU, respectively. As the other negative control for universal siRNA, Stealth RNAi Negative Control Duplexes (Medium GC Duplex) (Invitrogen) was used (NC). Cells were transfected with siRNA using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Cells (5×10^5 per well of a six-well plate) in suspending condition were transfected twice at 24 h interval (5 μ l of 20 μ M siRNA each) and analysed 48 h after second transfection.

A system stably expressing miRNA was generated using the BLOCK-iT Pol II miR RNAi Expression Vector Kit with

EmGFP (Invitrogen) according to the manufacturer's instructions. In the generation of the miR RNAi vector for humans, ShcC was chosen as the target sequence, using the top/bottom oligo sequence: 5'-TGCTGCTTGGAGGCTTTCTCTCTTT GGTTTTGGCCACTGACTGACCAAGAAGAAAGCCTC CAAG-3'/5'-CCTGCTTGGAGGCTTTCTCTTGGTCAGTC AGTGGCCAAAACCAAGAAGAGAAAGCCTCCAAGC-3'. Cells stably expressing the miR RNAi vector for ShcC (miShcC) and LacZ (miLacZ), that were also expressing green fluorescent protein were established and cultured in medium containing blasticidin (InvivoGen, San Diego, CA, USA) at a concentration of 15 μ g/ml for 3 weeks. Three clones expressing the ShcC RNAi vector were selected by significant suppression of the ShcC protein (<10%), and two clones from the control LacZ vector were also selected. Cells transfected with miR-negative control plasmid (one of kit components) were used as other control cells (Vec).

Generation of KU-YS cells stably expressing ShcA/ShcC

The full-length human ShcA cDNA for transfection was donated by Dr N Goto. ShcA and ShcC cDNAs were inserted with C-terminal Flag epitope tag into a mammalian expression vector pcDNA3.1A. All parts amplified by PCR were verified by sequencing. The stable expression of the full-length of ShcA and full-length of ShcC in KU-YS cells were obtained by transfection using transfection reagent Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. The KU-YS cells transfected with pcDNA3.1 vector (mock) were used as a control. Then, cells were selected according to the method described previously and the expression level of each independent clone was evaluated by immunoblotting analysis.

Acknowledgements

This work was supported by a Grant-in-Aid from the Ministry of Health, Labor and Welfare of Japan for the third-term Comprehensive 10-year Strategy for Cancer Control.

References

- Berwanger B, Hartmann O, Bergmann E, Bernard S, Nielsen D, Krause M et al. (2002). Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. *Cancer Cell* 2: 377-386.
- Brodeur GM, Nakagawara A. (1992). Molecular basis of clinical heterogeneity in neuroblastoma. *Am J Pediatr Hematol Oncol* 14: 111-116.
- Brouns MR, Matheson SF, Hu KQ, Delalle I, Caviness VS, Silver J et al. (2000). The adhesion signaling molecule p190 RhoGAP is required for morphogenetic processes in neural development. *Development* 127: 4891-4903.
- Brouns MR, Matheson SF, Settleman J. (2001). p190 RhoGAP is the principal Src substrate in brain and regulates axon outgrowth, guidance and fasciculation. *Nat Cell Biol* 3: 361-367.
- Dhillon AS, Meikle S, Peyssonnaud C, Grindlay J, Kaiser C, Steen H et al. (2003). A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation. *Mol Cell Biol* 23: 1983-1993.
- Giudici AM, Sher E, Pelagi M, Clementi F, Zanini A. (1992). Immunolocalization of secretogranin II, chromogranin A, and chromogranin B in differentiating human neuroblastoma cells. *Eur J Cell Biol* 58: 383-389.
- Hecht M, Papoutsis M, Tran HD, Wilting J, Schweigerer L. (2004). Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas. *Cancer Res* 64: 6109-6118.
- Hecker TP, Grammer JR, Gillespie GY, Stewart Jr J, Gladson CL. (2002). Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. *Cancer Res* 62: 2699-2707.
- Hinsby AM, Lundfald L, Ditlevsen DK, Korshunova I, Juhl L, Meakin SO et al. (2004). ShcA regulates neurite outgrowth stimulated by neural cell adhesion molecule but not by fibroblast growth factor 2: evidence for a distinct fibroblast growth factor receptor response to neural cell adhesion molecule activation. *J Neurochem* 91: 694-703.
- Iwamoto T, Taniguchi M, Wajiwalku W, Nakashima I, Takahashi M. (1993). Neuroblastoma in a transgenic mouse carrying a metallothionein/ret fusion gene. *Br J Cancer* 67: 504-507.
- Leever SJ, Paterson HF, Marshall CJ. (1994). Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. *Nature* 369: 411-414.
- Liu HY, Meakin SO. (2002). ShcB and ShcC activation by the Trk family of receptor tyrosine kinases. *J Biol Chem* 277: 26046-26056.
- Magrassi L, Conti L, Lanterna A, Zuccato C, Marchionni M, Cassini P et al. (2005). Shc3 affects human high-grade astrocytomas survival. *Oncogene* 24: 5198-5206.
- Marshall GM, Peaston AE, Hoeker JE, Smith SA, Hansford LM, Tobias V et al. (1997). Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion *in vitro*, enhances

- metastatic behavior *in vivo*, and activates Jun kinase. *Cancer Res* **57**: 5399–5405.
- Miyake I, Hakomori Y, Misu Y, Nakadate H, Matsuura N, Sakamoto M et al. (2005). Domain-specific function of ShcC docking protein in neuroblastoma cells. *Oncogene* **24**: 3206–3215.
- Miyake I, Hakomori Y, Shinohara A, Gamou T, Saito M, Iwamatsu A et al. (2002). Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. *Oncogene* **21**: 5823–5834.
- Moro L, Venturino M, Bozzo C, Silengo L, Altruda F, Beguinot L et al. (1998). Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival. *EMBO J* **17**: 6622–6632.
- Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. (1993). Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. *N Engl J Med* **328**: 847–854.
- Nakagawara A, Brodeur GM. (1997). Role of neurotrophins and their receptors in human neuroblastomas: a primary culture study. *Eur J Cancer* **33**: 2050–2053.
- Nakamura T, Komiya M, Gotoh N, Koizumi S, Shibuya M, Mori N. (2002). Discrimination between phosphotyrosine-mediated signaling properties of conventional and neuronal Shc adapter molecules. *Oncogene* **21**: 22–31.
- Nakamura T, Muraoka S, Sanokawa R, Mori N. (1998). N-Shc and Sck, two neuronally expressed Shc adapter homologs. Their differential regional expression in the brain and roles in neurotrophin and Src signaling. *J Biol Chem* **273**: 6960–6967.
- Nakamura T, Sanokawa R, Sasaki Y, Ayusawa D, Oishi M, Mori N. (1996). N-Shc: a neural-specific adapter molecule that mediates signaling from neurotrophin/Trk to Ras/MAPK pathway. *Oncogene* **13**: 1111–1121.
- O'Bryan JP, Lambert QT, Der CJ. (1998). The src homology 2 and phosphotyrosine binding domains of the ShcC adaptor protein function as inhibitors of mitogenic signaling by the epidermal growth factor receptor. *J Biol Chem* **273**: 20431–20437.
- O'Bryan JP, Songyang Z, Cantley L, Der CJ, Pawson T. (1996). A mammalian adaptor protein with conserved Src homology 2 and phosphotyrosine-binding domains is related to Shc and is specifically expressed in the brain. *Proc Natl Acad Sci USA* **93**: 2729–2734.
- Ohira M, Morohashi A, Inuzuka H, Shishikura T, Kawamoto T, Kageyama H et al. (2003). Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets. *Oncogene* **22**: 5525–5536.
- Opel D, Poremba C, Simon T, Debatin KM, Fulda S. (2007). Activation of Akt predicts poor outcome in neuroblastoma. *Cancer Res* **67**: 735–745.
- Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R. (2005). Biological role of anaplastic lymphoma kinase in neuroblastoma. *Am J Pathol* **167**: 213–222.
- Pellici G, Dente L, De Giuseppe A, Verducci-Galletti B, Giuli S, Mele S et al. (1996). A family of Shc related proteins with conserved PTB, CH1 and SH2 regions. *Oncogene* **13**: 633–641.
- Qui MS, Green SH. (1992). PC12 cell neuronal differentiation is associated with prolonged p21ras activity and consequent prolonged ERK activity. *Neuron* **9**: 705–717.
- Ravichandran KS. (2001). Signaling via Shc family adapter proteins. *Oncogene* **20**: 6322–6330.
- Sakai R, Henderson JT, O'Bryan JP, Elia AJ, Saxton TM, Pawson T. (2000). The mammalian ShcB and ShcC phosphotyrosine docking proteins function in the maturation of sensory and sympathetic neurons. *Neuron* **28**: 819–833.
- Schwab M, Westermann F, Hero B, Berthold F. (2003). Neuroblastoma: biology and molecular and chromosomal pathology. *Lancet Oncol* **4**: 472–480.
- Stokoe D, Macdonald SG, Cadwallader K, Symons M, Hancock JF. (1994). Activation of Raf as a result of recruitment to the plasma membrane. *Science* **264**: 1463–1467.
- Terui E, Matsunaga T, Yoshida H, Kouchi K, Kuroda H, Hishiki T et al. (2005). Shc family expression in neuroblastoma: high expression of shcC is associated with a poor prognosis in advanced neuroblastoma. *Clin Cancer Res* **11**: 3280–3287.
- Wary KK, Mainiero F, Isakoff SJ, Marcantonio EE, Giancotti FG. (1996). The adaptor protein Shc couples a class of integrins to the control of cell cycle progression. *Cell* **87**: 733–743.
- Wary KK, Mariotti A, Zurzolo C, Giancotti FG. (1998). A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. *Cell* **94**: 625–634.
- Wellbrock C, Weisser C, Geissinger E, Troppmair J, Scharl M. (2002). Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. *J Biol Chem* **277**: 6443–6454.
- Yaka R, Gamliel A, Gurwitz D, Stein R. (1998). NGF induces transient but not sustained activation of ERK in PC12 mutant cells incapable of differentiating. *J Cell Biochem* **70**: 425–432.
- Yamada M, Numakawa T, Koshimizu H, Tanabe K, Wada K, Koizumi S et al. (2002). Distinct usages of phospholipase C gamma and Shc in intracellular signaling stimulated by neurotrophins. *Brain Res* **955**: 183–190.

Supplementary Information accompanies the paper on the Oncogene website (<http://www.nature.com/onc>)

Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung

Jun-ichiro Ikeda,¹ Tomofumi Oda,^{1,2} Masayoshi Inoue,² Takamasa Uekita,³ Ryuichi Sakai,³ Meinoshin Okumura,² Katsuyuki Aozasa¹ and Eiichi Morii^{1,4}

Departments of ¹Pathology and ²Thoracic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, and ³Growth Factor Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan

(Received September 29, 2008/Revised November 4, 2008/Accepted November 19, 2008/Online publication December 11, 2008)

CUB domain containing protein (CDCP1), a transmembrane protein with intracellular tyrosine residues which are phosphorylated upon activation, is supposed to be engaged in proliferative activities and resistance to apoptosis of cancer cells. Expression level of CDCP1 was examined in lung adenocarcinoma, and its clinical implications were evaluated. CDCP1 expression was immunohistochemically examined in lung adenocarcinoma from 200 patients. Staining intensity of cancer cells was categorized as low and high in cases with tumor cells showing no or weak and strong membrane staining, respectively. MIB-1 labeling index was also examined. There were 113 males and 87 females with median age of 63 years. Stage of disease was stage I in 144 cases (72.0%), II in 19 (9.5%), and III in 37 (18.5%). Sixty of 200 cases (30.0%) were categorized as CDCP1-high, and the remaining as CDCP1-low. Significant positive correlation was observed between CDCP1-high expression and relapse rate ($P < 0.0001$), poor prognosis ($P < 0.0001$), MIB-1 labeling index ($P < 0.0001$), and occurrence of lymph node metastasis ($P = 0.0086$). There was a statistically significant difference in disease-free survival (DFS) ($P < 0.0001$) and overall survival (OS) rates ($P < 0.0001$) between patients with CDCP1-high and CDCP1-low tumors. Univariate analysis showed that lymph node status, tumor stage, and CDCP1 expression were significant factors for both OS and DFS. Multivariate analysis revealed that only CDCP1 expression was an independent prognostic factor for both OS and DFS. CDCP1 expression level is a useful marker for prediction of patients with lung adenocarcinoma (*Cancer Sci* 2009; 100: 429–433).

Introduction

Since 1985 lung cancer has been the most common cause of cancer death in the world.⁽¹⁾ Non-small cell lung cancer (NSCLC) comprises 75–85% of all lung cancers, and approximately two-thirds of NSCLC patients have advanced stages at diagnosis. Despite the advances in the methods for detection and treatment of lung cancer, prognosis of NSCLC patients still remains unfavorable. Therefore, it is important to clarify the mechanism of tumor biology, and establishment of effective therapeutic modalities is essential to improve the prognosis in NSCLC. Previous studies accumulated information regarding the factors influencing prognosis in NSCLC. They include clinical, pathological, and molecular factors.

CUB domain containing protein (CDCP1) was originally identified as an epithelial tumor antigen by comparisons of molecules expressed in lung cancer cell lines and normal lung tissues.⁽²⁾ CDCP1 is a transmembrane protein with three extracellular CUB domains, which are important for cell–cell interactions, and intracellular tyrosine residues which are phosphorylated upon activation.^(3–7) Previously, we reported the

epigenetic regulation of CDCP1 expression in the cell lines derived from various malignancies and clinical samples of breast cancer.^(8,9) The CDCP1 expression level correlated with proliferative activities of breast cancer cells in the clinical samples.⁽⁹⁾ Very recently, CDCP1 was reported to protect cells from anoikis, a form of apoptosis triggered by the loss of cell survival signals generated from interaction of cells with the extracellular matrix.⁽¹⁰⁾ The knocked-down expression of CDCP1 by RNA interference abolished *in vitro* colony formation and *in vivo* metastatic abilities of lung adenocarcinoma cell line A549.⁽¹⁰⁾ These findings showed that CDCP1 is required for protection of cells from anoikis, and suggest an important role of CDCP1 for tumorigenesis and metastasis, at least in cell lines. In the present study, CDCP1 expression was immunohistochemically examined in clinical samples from lung adenocarcinoma, and its clinical implications were evaluated.

Materials and Methods

Patients and tissue samples. Two hundred patients who underwent surgery for lung adenocarcinoma at Osaka University Hospital during the period from January 1993 to January 2004 were examined. Clinicopathological findings in these 200 patients are summarized in Table 1. There were 113 men and 87 women with ages ranging from 33 to 82 years (median, 63). Resected specimens were macroscopically examined to determine the location and size of the tumors. The size of the main tumor ranged from 8 to 70 mm (median, 24.5). The histological stage was determined according to the 6th edition of the Union International Contre le Cancer – TNM staging system.⁽¹¹⁾ Histologic specimens were fixed in 10% formalin and routinely processed for paraffin-embedding. Paraffin-embedded specimens were stored in the dark room in the Department of Pathology of Osaka University Hospital at room temperature, and were sectioned at 4- μ m thickness at the time of staining. In some cases, total RNA was extracted using RNeasy kit (Qiagen, Valencia, CA, USA) with DNase I treatment. All patients were followed up with laboratory examinations including routine peripheral blood cell counts at 1- to 6-month intervals, chest roentgenogram, computed tomographic scan of the chest, and endoscopic examinations of the bronchus at 6- to 12-month intervals. The follow-up period for survivors ranged from 5 to 154 months (median, 63). The study was approved by the ethical review board of the Graduate

This work is original, and contains no materials previously presented in any reports and publications.

*To whom correspondence should be addressed.

E-mail: morii@patho.med.osaka-u.ac.jp




Fig. 1. Surface staining of CDCP1-low (A and B) and -high (C and D) cases, $\times 400$ (E) Real-time reverse transcription-polymerase chain reaction. The amount of CDCP1 mRNA was significantly higher in immunohistochemically defined CDCP1-high cases than in CDCP1-low cases. The bar shows mean values of the amount of CDCP1 mRNA. * $P < 0.01$

Table 1. Summary of characteristics in 200 pulmonary adenocarcinoma patients

Sex	Number of patients
Male	113
Female	87
Tumor size (cm)	
≥ 5	12
< 5	187
Lymph node metastasis	
N0	159
N1	8
N2	29
N3	4
Stage	
I	144
II	19
III	37
Recurrence	
Positive	60
Negative	140
Prognosis	
Dead	41
Alive (with recurrence)	24
Alive (with no recurrence)	135

School of Medicine, Osaka University. Informed consent was obtained from each patient.

Immunohistochemistry for CDCP1, phosphorylated CDCP1 and Ki-67. CDCP1 expression was immunohistochemically examined with use of anti-CDCP1 (Abcam Ltd, Cambridge, UK) and antiphosphorylated CDCP1 antibody. The antiphosphorylated CDCP1 antibody recognizes CDCP1 phosphorylated at Tyr734 and can be used for immunostaining on paraffin-embedded sections.^(10,12) The proliferative activity of cancer cells was examined with monoclonal antibody MIB-1 (Immunotech, Marseilles, France), recognizing the proliferation-associated antigen Ki-67. After antigen retrieval with Pascal pressurized heating chamber (Dako, Glostrup, Denmark), the sections were incubated with anti-CDCP1, phosphorylated CDCP1 antibody and MIB-1, diluted at $\times 200$, $\times 400$ and $\times 100$, respectively. Then, the sections were treated with biotin-conjugated antigoat IgG (Zymed, San Francisco, CA, USA) for CDCP1 staining, or with biotin-conjugated antimouse IgG (Dako) for phosphorylated CDCP1 and MIB-1 staining. After washing, the sections were incubated with the peroxidase-conjugated biotin-avidin complex (Vectastain ABC kit, Vector

Laboratories, Burlingame, CA, USA), diaminobenzidine (Vector Laboratories) was used as a chromogen. As the negative control, staining was carried out in the absence of a primary antibody. Stained sections were evaluated independently by two pathologists (JI and EM). Generally, CDCP1 expression levels varied among tumor cells in the same case. Staining intensity of tumor cells was divided into four categories; tumor cells with no (representative field was demonstrated in Fig. 1A), weak (Fig. 1B), moderate (Fig. 1C), or strong (Fig. 1D) membrane staining. The intensity of CDCP1 expression in each case was defined by the major population of staining as follows: cases with tumor cells showing no or weak membrane staining were categorized as CDCP1-low, and those showing moderate or strong membrane staining as CDCP1-high. The MIB-1 labeling index was defined as the percentage of stained nuclei per 1000 cells. The cases were divided into MIB-1-high and MIB-1-low groups using the median as cut-off value.

Quantification of mRNA by real-time reverse transcription-polymerase chain reaction (RT-PCR). To evaluate the specificity of CDCP1 immunostaining, expression level of CDCP1 at mRNA and protein levels was compared. For this, fresh frozen materials were available in 13 of the 200 cases. Total RNA was extracted using RNeasy kit (Qiagen, Valencia, CA, USA) with DNase I treatment. Two micrograms of total RNA was subjected to reverse transcription using Superscript III (Invitrogen, Carlsbad, CA, USA). The mRNA levels for CDCP1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes were verified using TaqMan Gene Expression Assays (Hs00224587_m1 and 4310884E, respectively; Applied Biosystems, Foster City, CA, USA) as recommended by the manufacturer. The amount of CDCP1 mRNA was normalized to that of GAPDH mRNA.

Statistical analysis. Statistical analyses were performed using StatView software (SAS Institute Inc., Cary, NC, USA). The Chi-square and Fisher's exact probability test were used to analyze the correlation between CDCP1 expression and clinicopathological factors in pulmonary adenocarcinoma. Kaplan-Meier methods were used to calculate overall survival (OS) and disease-free survival (DFS) rate, and differences in survival curves were evaluated with the log-rank test. Cox's proportional hazards regression model with a stepwise manner was used to analyze the independent prognostic factors. The P -values of less than 0.05 were considered to be statistically significant.

Results

Tumor stages in the present patients were: stage I in 144 patients (72.0%); II in 19 patients (9.5%); and III in 37 patients (18.5%). The histological types of tumors were: bronchioloalveolar




Fig. 2. Localization of phosphorylated CDCP1 in lung adenocarcinoma. Stained cells with anti-CDCP1 antibody (A), and antiphosphorylated CDCP1 antibody (B). Among the CDCP1-positive tumor cells, peripheral areas of tumor cell nests were stained with antiphosphorylated CDCP1 antibody, $\times 400$.

(62 patients, 31.0%); papillary (48 patients, 24.0%); or mixed bronchioloalveolar and papillary adenocarcinoma (90 patients, 45.0%). The 5-year DFS and OS was 78.7% and 80.6%, respectively. Tumors recurred in 60 patients. Of these, 38 patients died due to the tumors.

To evaluate the specificity of immunohistochemical staining for CDCP1 expression, quantitative real-time RT-PCR was performed: expression levels of CDCP1 at protein and mRNA level was compared in 13 cases (3 CDCP1-high and 10 CDCP1-low cases at immunohistochemical results). The amount of CDCP1 mRNA was significantly higher in cases with CDCP1-high expression at immunohistochemistry than those with CDCP1-low expression ($P < 0.01$, Fig. 1E). These results showed that the immunohistochemical evaluation is a reliable method for evaluation of CDCP1 expression.

Immunohistochemical detection of CDCP1 expression was carried out in 200 lung adenocarcinoma tissues. Sixty of 200 cases (30.0%) were categorized as CDCP1-high, and the remaining as CDCP1-low. Representative staining results were illustrated in Fig. 1(A-D).

Intracellular tyrosine residues of CDCP1 are known to be phosphorylated upon activation *in vitro*. To examine the localization of activated CDCP1, 43 cases of CDCP1-high lung adenocarcinoma tissues were stained with antiphosphorylated CDCP1. Phosphorylated CDCP1 was detected only in a small portion of CDCP1-expressing cells (Fig. 2 A and 2B), which

Table 2. Correlation between CDCP1 expression and clinicopathological parameters

	CDCP1 expression		P
	Low	High	
Tumor size (cm)			
≥ 5	7	5	
< 5	133	55	0.3630
Lymph node metastasis			
N0	120	39	
N1	3	5	
N2	15	14	
N3	2	2	0.0086
Stage			
I	110	34	
II	11	8	
III	19	18	0.0059
MIB-1 labeling index			
$\geq 5\%$	56	45	
$< 5\%$	84	15	< 0.0001
Recurrence			
Positive	23	37	
Negative	117	23	< 0.0001
Prognosis			
Dead	17	24	
Alive (with recurrence)	10	14	
Alive (with no recurrence)	113	22	< 0.0001

appeared to be localized to the peripheral areas of tumor cell nests. Cells without CDCP1 expression did not show any phosphorylated CDCP1 signals, indicating the specificity of the antiphosphorylated CDCP1 antibody. Phosphorylated CDCP1 was detected in 19 out of 43 cases; any significant clinicopathological differences were not observed between cases with and without phosphorylated CDCP1.

Correlation of CDCP1 expression with the clinicopathological features was evaluated. Significant positive correlation was observed between CDCP1-high expression and relapse rate ($P < 0.0001$), poor prognosis ($P < 0.0001$), MIB-1 labeling index ($P < 0.0001$), and occurrence of lymph node metastasis ($P = 0.0086$). Other parameters including tumor size and stage did not correlate with CDCP1 expression (Table 2). There was a statistically significant difference in DFS rates ($P < 0.0001$) and OS rates ($P < 0.0001$) between patients with CDCP1-high and CDCP1-low tumors (Fig. 3).

Univariate analysis showed that lymph node status, tumor stage, and CDCP1 expression were significant factors for both OS and DFS (Table 3). The multivariate analysis revealed that only CDCP1 expression was an independent prognostic factor for both OS and DFS.

Discussion

Patient characteristics such as the gender (male preponderance), age distribution (median age, 6th decades of life), and 5-year OS of approximately 80% in the present study were similar to those in a previous report on the lung adenocarcinoma.⁽¹³⁾ In addition, the univariate analysis showed the prognostic significance of occurrence of lymph node metastasis and stage of disease, as reported previously.⁽¹³⁾ These findings indicate that the results obtained from the present cases are commonly applicable.

Among the clinicopathological factors examined, high CDCP1 expression level correlated with increased occurrence of lymph node metastasis and tumor relapse. A previous study using the lung adenocarcinoma cell lines indicated a significant role of CDCP1 for anchorage-independent growth of tumor cells.⁽¹⁰⁾

Table 3. Univariate and multivariate analyses of prognostic factors for overall and disease-free survivals

	Overall survival				Disease-free survival			
	Univariate		Multivariate		Univariate		Multivariate	
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Tumor size	1.07 (0.79-1.43)	0.672			1.11 (0.86-1.45)	0.425		
Lymph node status	2.34 (1.77-3.08)	<0.001	1.46 (0.85-2.50)	0.167	2.40 (1.82-3.17)	<0.001	1.43 (0.84-2.40)	0.182
Stage	2.64 (1.90-3.69)	<0.001	1.63 (0.87-3.06)	0.128	2.77 (1.99-3.86)	<0.001	1.74 (0.95-3.20)	0.074
MIB-1 labeling index	1.46 (0.78-2.74)	0.235			1.44 (0.77-2.69)	0.250		
CDCP1 expression	4.11 (2.18-7.75)	<0.001	2.89 (1.51-5.54)	0.001	4.32 (2.31-8.08)	<0.001	3.04 (1.60-5.80)	<0.001

HR, hazard ratio; CI, confidence interval.




Fig. 3. Kaplan-Meier plots of disease-free (A) and overall survival (B) of patients.

The knocked-down expression of CDCP1 abolished ability of *in vitro* colony formation in the A549 lung adenocarcinoma cell line.⁽¹⁰⁾ In addition, when injected into nude mice, the number of metastatic nodules was low in CDCP1-knocked down A549 cells as compared to parental A549 cells.⁽¹⁰⁾ Taken together with the present results, CDCP1 appeared to play important roles for metastatic and tumorigenic potentials of lung adenocarcinoma not only in cell lines but also in clinical samples.

High CDCP1 expression was correlated with MIB-1 labeling index. Since the monoclonal antibody MIB-1 recognizes Ki-67 antigen that is expressed in cells during the cell cycle, except at the G0 phase, it can be applied to evaluate the proliferative

activities of cells. Previously, we showed the positive correlation of CDCP1 expression with MIB-1 labeling index in breast cancer cells.⁽⁸⁾ These findings indicate that CDCP1 expression level reflects a proliferative activity of cancer cells.

Intracellular tyrosine residues of CDCP1 are known to be phosphorylated upon activation, and the level of tyrosine phosphorylation is associated with the capacity for anchorage independence in A549 cells.⁽¹⁰⁾ Immunohistochemically, phosphorylated CDCP1 was found to be localized to the peripheral areas of tumor cell nests. Lung adenocarcinoma cells often show bronchioalveolar growth in the periphery of the cancer tissues, but such portions were almost negative for phosphorylated CDCP1 expression. Phosphorylated CDCP1 was mostly present in the tumor cells expanding to the surrounding normal tissues. This was consistent with the previous report that phosphorylated CDCP1 is localized in the invasive front of gastric cancer.⁽¹²⁾ Therefore, phosphorylated CDCP1 may play some roles for tumor invasion, in addition to anchorage independence. The staining for phosphorylated and non-phosphorylated CDCP1 demonstrated that most tumor cells expressed CDCP1 as a non-phosphorylated form. This was consistent with the report by Brown *et al.* that the phosphorylation of CDCP1 is dynamically balanced by Src-family kinase and phosphotyrosine phosphatase activities, yielding low equilibrium phosphorylation.⁽⁶⁾ CDCP1 contains three extracellular CUB domains, which might be involved in cell adhesion or interaction with the extracellular matrix.⁽²⁻⁷⁾ Non-phosphorylated CDCP1 may function as an adhesion molecule.

Multivariate analysis revealed the high expression of CDCP1 to be an independent factor for poor prognosis for patients with lung adenocarcinoma. Benes *et al.* reported that Src, which mediates proliferation signals in cancers, forms a complex with phosphorylated CDCP1.⁽⁷⁾ These findings indicate that overexpression of CDCP1 could stimulate tumor growth, explaining why prognosis of patients with CDCP1-high tumors is worse than that with CDCP1-low tumors.

In conclusion, high CDCP1 expression is an independent factor for poor prognosis of patients with lung adenocarcinoma. Further studies will be necessary to elucidate whether CDCP1 expression could be a useful marker for prediction of prognosis in other types of cancers. CDCP1 could be a molecular target for cancer therapy.

Acknowledgments

The authors thank Ms. Megumi Sugano and Ms. Takako Sawamura for their technical assistance. This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology, and from the Osaka Cancer Research Foundation.

References

- 1 Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. *CA Cancer J Clin* 2005; **55**: 74-108.
- 2 Scherl-Mostageer M, Sommergruber W, Abseher R, Hauptmann R, Ambros P, Shweifer N. Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. *Oncogene* 2001; **20**: 4402-8.
- 3 Hooper JD, Zijlstra A, Aimes RT *et al*. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. *Oncogene* 2003; **22**: 1783-94.
- 4 Conze T, Lammers R, Kuci S *et al*. CDCP1 is a novel marker for hematopoietic stem cells. *Ann NY Acad Sci* 2003; **996**: 222-6.
- 5 Buhning H-J, Kuci S, Conze T *et al*. CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin. *Stem Cells* 2004; **22**: 334-43.
- 6 Brown TA, Yang TM, Zaitsevskaia T *et al*. Adhesion or plasmin regulates tyrosine phosphorylation of a novel membrane glycoprotein p80/gp140/CUB domain-containing protein 1 in epithelia. *J Biol Chem* 2004; **279**: 14772-83.
- 7 Benes CH, Wu N, Elia AEH, Dharis T, Cantley LC, Soltoff SP. The C2 domain of PKC-delta is a phosphotyrosine binding domain. *Cell* 2005; **121**: 271-80.
- 8 Ikeda JI, Morii E, Kimura H *et al*. Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells. *J Pathol* 2006; **210**: 75-84.
- 9 Kimura H, Morii E, Ikeda JI *et al*. Role of DNA methylation for expression of novel stem cell marker CDCP1 in hematopoietic cells. *Leukemia* 2006; **20**: 1551-6.
- 10 Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T, Sakai R. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. *Mol Cell Biol* 2007; **27**: 7649-60.
- 11 Sobin LH, Wittekind Ch, eds. *TNM Classification of Malignant Tumors*, 5th edn. New York: John Wiley & Sons, Inc., 1997.
- 12 Uekita T, Tanaka M, Takigahira M *et al*. CUB domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. *Am J Pathol* 2008; **172**: 1729-39.
- 13 Suzuki K, Nagai K, Yoshida J *et al*. Conventional Clinicopathologic Prognostic Factors in Surgically Resected Nonsmall Cell Lung Carcinoma. *Cancer* 1999; **86**: 1976-84.

Association of Estrogen Receptor α and Histone Deacetylase 6 Causes Rapid Deacetylation of Tubulin in Breast Cancer Cells

Kotaro Azuma,¹ Tomohiko Urano,^{1,2} Kuniko Horie-Inoue,⁴ Shin-ichi Hayashi,⁵ Ryuichi Sakai,³ Yasuyoshi Ouchi,¹ and Satoshi Inoue^{1,2,4}

Departments of ¹Geriatric Medicine and ²Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo and ³Growth Factor Division, National Cancer Center Research Institute, Tokyo, Japan; ⁴Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical School, Saitama, Japan; and ⁵Department of Medical Technology, Course of Health Sciences, School of Medicine, Tohoku University, Miyagi, Japan

Abstract

Estrogen receptor α (ER α) is a nuclear receptor that functions as a ligand-activated transcription factor. Besides its genomic action in nuclei, ER α could exert nongenomic actions at the plasma membrane. To investigate the mechanism underlying the nongenomic action of ER α in breast cancer cells, we generated a construct of membrane-targeted ER α (memER), an expression vector of ER α without the nuclear localizing signal and including instead the membrane-targeting sequence of Src kinase. MemER was stably expressed in human breast cancer MCF-7 cells. Cell migration test and tumorigenic assay in nude mice revealed that the *in vitro* motility and the *in vivo* proliferation activity of MCF-7 cells expressing memER were significantly enhanced compared with those of vector-transfected cells. Interestingly, the acetylation level of tubulin in memER-overexpressing cells was lower than that in control cells. We found that histone deacetylase (HDAC) 6 translocated to the plasma membrane shortly after estrogen stimulation, and rapid tubulin deacetylation subsequently occurred. We also showed that memER associated with HDAC6 in a ligand-dependent manner. Although tamoxifen is known for its antagonistic role in the ER α genomic action in MCF-7 cells, the agent showed an agonistic function in the memER-HDAC6 association and tubulin deacetylation. These findings suggest that ER α ligand dependently forms a complex with HDAC6 and tubulin at the plasma membrane. Estrogen-dependent tubulin deacetylation could provide new evidence for the nongenomic action of estrogen, which potentially contributes to the aggressiveness of ER α -positive breast cancer cells. [Cancer Res 2009;69(7):2935–40]

Introduction

Estrogen plays an essential role in various biological and pathologic processes, particularly in the development of breast cancer (1). Estrogen exerts its function by activating its corresponding nuclear receptor, estrogen receptor α (ER α). ER α is a ligand-dependent transcription factor that forms complexes with coactivators and histone acetyltransferases in response to agonists. The acetylation of histones changes the chromatin conformation and activates transcription pathways. In contrast, ER α forms complexes with corepressors and histone deacetylases

(HDAC) in the treatment with antagonists. The deacetylation of histones alters the chromatin conformation into a transcriptionally inactive form. The expression status of ER α and its primary target progesterone receptor is important in the management of breast cancer, as ER α - and progesterone receptor-positive tumors are known to respond to antiestrogenic treatment. Tamoxifen has been used for years as a prototypic selective estrogen receptor modulator for endocrine therapy in breast cancer.

Recently, it has been shown that ER α has an alternative function that mediates specific signals through the association with molecules outside the nuclei, in addition to its known activity of transcriptional regulation (2). In vascular endothelial cells, estrogen rapidly induces nitric oxide production by activating the phosphatidylinositol-3-OH kinase pathway (3). In osteoblasts and fibroblasts, ER α mediates an antiapoptotic effect by activating the Src-Shc-Erk pathway, predominantly through the action of the activation function 2 domain (4). These phenomena are known as nongenomic actions, which may be distinct from the classic genomic actions of ER α because of their rapid time course and the subcellular localization of the molecules interacting with ER α .

Ligand-dependent rapid phosphorylation of MAP kinases, another example of nongenomic action by estrogen, has been also revealed in ER α -positive breast cancer MCF-7 cells (5). We showed previously that a subset of ER α in MCF-7 cells translocated to the plasma membrane in response to estradiol (E₂), and the activation function 1 (AF-1) domain of ER α interacted with polymerized tubulin when the AF-1 domain of ER α was expressed at the plasma membrane with the membrane-targeting signal (6).

Recently, HDAC6, a class IIB zinc-dependent HDAC predominantly localized in the cytoplasm, has been shown to deacetylate tubulin (7). Tubulin is the major component of microtubules, which play a critical role in the cell migration, cell morphology, cell-cell interaction, and tumor metastasis. In breast cancer, HDAC6 expression was induced in response to estrogen, and HDAC6 overexpression was reported as a poor prognostic factor (8). It has been also shown that the motility of breast cancer cells could be enhanced by HDAC6 overexpression and reduced by the inhibition of HDAC6 activity (9).

In the present study, we show a novel nongenomic action of estrogen in breast cancer cells, as the membrane-localized ER α associates with HDAC6 and causes rapid deacetylation of tubulin in a ligand-dependent manner.

Materials and Methods

Antibodies and reagents. Anti-Myc, anti-ER α (H-184), anti-HDAC6, and anti-HA polyclonal antibodies were purchased from Santa Cruz Biotechnology. Anti-FLAG M2 and M5 monoclonal, anti- α -tubulin (B-5-1-2), and anti-acetylated- α -tubulin (6-11B-1) antibodies were purchased from

Requests for reprints: Satoshi Inoue, Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Phone: 81-3-5800-8652; Fax: 81-3-5800-6530; E-mail: INOUE-GER@hu-tokyo.ac.jp

©2009 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-08-3458




Figure 1. Generation of MCF-7 cells stably expressing memER. *A*, Schematic representation of full-length ER α and memER. *B*, Western blot analysis of MCF-7 cells stably expressing memER (*memER* #1 and #2) and vector clones (*vec* #1 and #2). Whole cell lysates were immunoblotted with anti-Myc and anti- α -tubulin antibodies. *C*, Immunocytochemistry of MCF-7 clones expressing *vec* #1 and memER #1. Immunostaining with anti-FLAG (M2) antibody shows membrane localization of ER α protein in memER #1 clone. DAPI staining shows the cell nuclei. Cells were visualized with fluorescence microscopy at a $\times 600$ magnification. The memER #1 clone stained with anti-FLAG antibody is enlarged in the inset.

SIGMA. Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 594 goat anti-rabbit IgG were purchased from Molecular Probe. Horseradish peroxidase-conjugated anti-mouse and anti-rabbit antibodies were purchased from Amersham Pharmacia. 17β -estradiol (E_2) and tamoxifen were purchased from SIGMA. HA-peptide was purchased from Roche.

Plasmids. Membrane-targeted ER α (memER) with FLAG and Myc epitope tags (memER Δ NLS-FLAG-Myc, memER) was generated in two steps. In the first step, an expression construct of ER α with an NH $_2$ -terminal membrane-targeting sequence (derived from the NH $_2$ terminus of Src kinase; MGSNKSQPKDASQ) and COOH-terminal FLAG and Myc tags was generated. In the second step, the sequence coding the nuclear localizing signal (NLS, 256-303 amino acids of ER α ; ref. 10) was deleted by PCR-based site-directed mutagenesis from the plasmid generated in the first step. The AF-1 and activation function 2 domains of ER α with the NH $_2$ -terminal membrane-targeting sequence and COOH-terminal FLAG tag (memAF1 and memAF2, respectively) were generated as previously described (6). Deletion mutants of HDAC6 with the COOH-terminal HA tag were generated by inserting HDAC6 amplicons in pcDNA3.1(-)/Myc-His 3, including the following amino acid numbers of the HDAC protein as

follows: full-length HDAC6 (full), 1-1215; Δ ZnF, 1-998; Δ DD2-ZnF, 1-408; Δ DD1, 409-1215; Δ DD1-DD2, 999-1215.

Cell culture and transfection. MCF-7, COS-7, and HEK293T cells were maintained in DMEM with 10% FCS at 37°C under 5% CO $_2$. MCF-7 and 293T cells were cultured in estrogen-starved medium (phenol red-free DMEM with 5% charcoal/dextran-treated FCS) for 2 d before E_2 /tamoxifen treatment. Transfection was performed using FuGENE 6 (Roche). To establish stable transfectants, MCF-7 clones were selected using G418 (SIGMA) at a concentration of 800 μ g/mL.

Immunoblotting and immunoprecipitation. Immunoblotting and immunoprecipitation were performed as previously described (6). For immunoprecipitation with the anti-HA antibody, aliquots of protein were mixed with anti-HA agarose conjugate (SIGMA).

Immunocytochemistry. Immunocytochemical analysis was performed as described (6). Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI; SIGMA) diluted with PBS (1:10,000) for 10 min. Cells were visualized with a fluorescence microscope (KEYENCE) or Radiance 2100 confocal microscope (BIO-RAD).

Cell migration assay. The cell migration assay was performed as previously described (11). The number of MCF-7 cells migrating through a polyethylene terephthalate filter with 8- μ m pores (Becton Dickinson) in 24 h was counted under microscopic examination.

Cell proliferation assay. Cells were seeded in 96-well plates at a density of 1,000 cells per well. The viable cell number was quantified using tetrazolium salt (WST-8) that could be converted to a water-soluble formazan by metabolically active cells. Spectrophotometric absorbance for formazan dye was measured at 450 nm, with absorbance at 655 nm as reference.

In vivo tumor growth assay. The *in vivo* tumor growth assay was basically performed as previously described (12). Four-week-old female BALB/c nude mice were ovariectomized, and a 17β -estradiol pellet (0.72 mg; 90-d release; Innovative Research of America) was s.c. transplanted in the right shoulder of each mouse. For s.c. implantation of tumor cells, 1 million cells suspended in 100 μ L of DMEM with 5% FCS were mixed with Matrigel and implanted in the left shoulder of ovariectomized nude mice. Tumor size was weekly measured at 2 to 6 wk after implantation, and tumor volume was determined using the tumor radius. Relative tumor volume was determined by normalizing to the mean value at 2 wk after implantation.

Statistical analyses. Differences between the mean values of memER-expressing MCF-7 clones and vector-expressing clones were analyzed using the Student's *t* test.

Results

Establishment of cell lines stably expressing memER. To analyze the function of membrane-localized ER α , we generated an expression vector of memER that contains the NH $_2$ -terminal membrane-localizing sequence derived from Src kinase and lacks the NLS (Fig. 1A; ref. 10). Src kinase is a nonreceptor tyrosine kinase localizing at the plasma membrane with its myristoylated NH $_2$ -terminal sequence. We established breast cancer MCF-7 cells stably expressing memER and the control vector (Fig. 1B). Immunocytochemical staining revealed that memER was predominantly expressed at the plasma membrane (Fig. 1C).

Enhanced motility and *in vivo* tumorigenesis of MCF-7 cells stably expressing memER. To elucidate the function of membrane-localized ER α , the motility of MCF-7 clones stably expressing memER and control vector was evaluated. The number of cells migrating through the 8- μ m-pored polyethylene terephthalate filter in 24 h was counted. The motility of memER overexpressing MCF-7 cells (*memER* #1 and #2) was significantly higher than that of vector clones (*vec* #1 and #2; Fig. 2A). To exclude the possibility that the difference in the growth affected the cell migration, the growth rate of each clone was measured. The growth rates of memER overexpressing clones had not apparently increased

compared with control cells (Fig. 2B). Next, we investigated the contribution of membrane-localized ER to *in vivo* tumorigenesis by using a nude mouse xenograft model. To avoid the effect of endogenous estrogen production, nude mice were ovariectomized and estrogen pellets were inserted s.c. The results showed that tumors derived from memER clones (*memER* #1 and #2) were larger than those from vector clones (*vec* #1 and #2; Fig. 2C and D). Taken together, these results indicate that the overexpression of memER facilitates cell migration activity in cultured cells as well as *in vivo* tumor formation of breast cancer cells.

Rapid tubulin deacetylation as a novel nongenomic action of estrogen. We have previously revealed that tubulin could associate with the membrane-targeted AF-1 domain of ER α in MCF-7 cells (6). Tubulin is an important component of the microtubule network that regulates cell motility, which could be enhanced by HDAC6 that deacetylates tubulin (7). Thus, we investigated whether memER overexpression could modulate the acetylation status of tubulin in MCF-7 cells. Tubulin acetylation was reduced in memER-expressing clones compared with vector clones (Fig. 3A).

We next assessed whether HDAC6 is involved in the regulation of tubulin acetylation in breast cancer cells. To confirm tubulin deacetylating activity of HDAC6, exogenous HDAC6 was transiently overexpressed in COS-7 cells and the acetylation status of endogenous tubulin was evaluated. HDAC6 overexpression apparently reduced tubulin acetylation in COS-7 cells (Fig. 3B). We investigated whether subcellular localization of endogenous HDAC6 together with tubulin could be altered by estrogen treatment in MCF-7 cells. Distribution of HDAC6 and α -tubulin was increased in submembrane and membrane protruded regions by E₂ compared with vehicle treatment (Fig. 3C). We next investigated whether the acetylation status of endogenous tubulin in MCF-7 cells was altered by E₂ stimulus. In this experiment, tamoxifen, a known antagonistic ligand for the genomic action of ER α in MCF-7 cells, was also used. Notably, the acetylation levels of α -tubulin were reduced by both E₂ and tamoxifen treatment for 15 min in MCF-7 cells (Fig. 3D). These findings lead us to hypothesize that estrogen facilitates the rapid membrane translocation of ER α and HDAC6, which functionally




Figure 2. Enhanced motility and *in vivo* tumorigenesis of MCF-7 cells expressing memER. **A**, enhanced motility of memER-expressing MCF-7 cells. Number of cells migrating through a polyethylene terephthalate filter with 8- μ m pores was counted for each clone. Top, cells on the lower side of the filters were stained with Giemsa's staining solution and visualized under a microscope. Representative views used to count the cells are shown at a $\times 200$ magnification. Magnified views of membrane pores and migrating cells are shown in the insets. Bottom, columns, mean number of cells counted in five fields; bars, SE. **B**, MemER expression does not markedly affect *in vitro* cell proliferation. MCF-7 clones were seeded at a density of 1,000 cells per well and the cell growth was assayed using WST-8 tetrazolium salt. Columns, mean of relative absorbance at 450 nm for each clone normalized to values at day 0 ($n = 4$); bars, SE. N.S., not significant. **C**, growth of xenograft derived from MCF-7 clones expressing memER is significantly accelerated compared with vector clones. Xenografts were established by s.c. implantation of MCF-7 clones in nude mice (one million cells per mouse). Tumor volume is shown by fold change normalized to the value at 2 wk after implantation. Points, mean of relative tumor volume (*vec* #1, $n = 4$; *vec* #2, $n = 3$; *memER* #1, $n = 4$; *memER* #2, $n = 7$); bars, SE. **D**, photographs of representative mice 8 wk after the implantation of MCF-7 clones. Arrowhead, tumor mass.




Figure 3. Estrogen reduces tubulin acetylation and translocates HDAC6 to the plasma membrane in MCF-7 cells. **A**, tubulin in memER-expressing MCF-7 clones is less acetylated. Whole cell lysates of indicated clones were immunoblotted with anti-Myc (top), anti-acetyl- α -tubulin (middle), and anti- α -tubulin (bottom). **B**, tubulin deacetylase activity of HDAC6. COS-7 cells were transiently transfected with empty or HDAC6-FLAG vectors. Cells were lysed at 24 h after transfection and immunoblotted with anti-acetyl- α -tubulin (top), anti- α -tubulin (middle), and anti-FLAG (M5; bottom). **C**, rapid translocation of HDAC6 to the plasma membrane in response to estrogen. MCF-7 cells were grown in an estrogen-starved medium for 48 h and treated with 17 β -estradiol (E₂; 10 nmol/L) or vehicle (0.1% ethanol) for 15 min. Cells were immunostained with anti- α -tubulin (green) and anti-HDAC6 (red) and visualized with fluorescence microscopy at a \times 600 magnification. Concentration of HDAC6 immunoreactivity at the plasma membrane is shown in E₂-stimulated cells. **Enlarged panels**, magnified views of a part of the top panels. Membrane protrusions (white arrowheads) are shown in enlarged panels of E₂-stimulated cells. **D**, rapid deacetylation of tubulin in MCF-7 cells with estrogen stimulation. MCF-7 cells were treated with E₂ (100 nmol/L), tamoxifen (TAM; 10 μ mol/L), or vehicle (Et) for 15 min. Whole-cell lysates before (T=0) and after drug treatment were immunoblotted with anti-acetyl- α -tubulin (top), anti- α -tubulin (top middle), anti-ER α (bottom middle), and HDAC6 (bottom). The acetylated level of tubulin is reduced in lysates from E₂- and tamoxifen-stimulated cells.

interact with the microtubule network and cause tubulin deacetylation.

Ligand-dependent association of HDAC6 with ER α . To prove the hypothesis that ER α associates with HDAC6 at the plasma membrane, memER and HA-tagged HDAC6 were cotransfected in 293T cells. An immunoprecipitation study verified the physical interaction of memER and HDAC6 proteins in an E₂-dependent manner. Tamoxifen also induced a weak interaction between memER and HDAC6 (Fig. 4A).

To analyze the responsible domains for the association of HDAC6 and memER, we generated a series of HA-tagged HDAC6 expression vectors with various functional domains deleted (Fig. 4B). HDAC6 includes two deacetylase domains (DD1 and DD2) and one ubiquitin carboxyl-terminal hydrolase-like zinc finger domain (ZnF-UBP). A transfection study revealed that these HDAC6 deletion mutants were expressed predominantly in the cytoplasm (data not shown). As ER α deletion mutants, we used memAF1 and memAF2 expression vectors, including the entire A/B region of ER α containing the AF-1 domain and the entire E/F region containing the activation function 2 domain, respectively, with an NH₂-terminal membrane-targeted sequence. We previously showed that these ER α deletion mutants were predominantly localized in the cytoplasm (6). The immunoprecipitation study revealed that the membrane-targeted activation function 2 domain associated with HDAC6 (Fig. 4C), and the DD2 domain of HDAC6 was responsible for the interaction with memER (Fig. 4D).


Discussion

Posttranslational modification is an important factor for the regulation of protein structure and function. Phosphorylation by protein kinases such as phosphatidylinositol-3-OH kinase and mitogen-activated protein kinase has been shown to play a critical role in estrogen-dependent nongenomic action. In the present study, we show that estrogen caused the formation of the ER α -HDAC6-tubulin complex at the plasma membrane and rapid tubulin deacetylation in MCF-7 breast cancer cells. Our findings show a novel aspect of estrogen nongenomic action that is regulated by tubulin acetylation, which is distinct from the previously reported mechanism dependent on protein phosphorylation.

In MCF-7 cells, estrogen-dependent tubulin deacetylation would be one of the driving forces of cell motility, as the microtubule network including tubulin is a critical element in cell migration. Our findings are consistent with a previous report that HDAC6 overexpression caused tubulin deacetylation and enhanced motility of breast cancer cells and the inhibition of HDAC6 activity reduced motility (9). HDAC6 inhibition is also considered to decrease turnover of focal adhesion, an interface between the cell membrane and the extracellular matrix. Decreased turnover of focal adhesion results in reduced cell motility (13).

It is also notable that memER accelerated tumor growth of MCF-7 cells in nude mice without enhancing cell proliferation *in vitro*. *In vivo* tumor growth differs from *in vitro* proliferation in the aspect that *in vivo* tumor growth requires several factors including anoikis resistance, angiogenesis, and survival in the hypoxic environment. Anoikis is a form of apoptosis caused by absence of attachment to the extracellular matrix (14). It was reported recently that HDAC6 is critical for anoikis resistance and *in vivo* tumorigenic growth with human ovarian cancer SKOV3 cells (15). In another report, stability of microtubules was shown to be associated with anoikis through alteration of the focal adhesion

Figure 4. MemER associates with HDAC6. **A**, ligand-dependent association of memER and HDAC6. 293T cells were grown in estrogen-starved medium for 24 h and cotransfected with memER and HDAC6-FLAG. After 24-h incubation, cells were treated with E₂ (100 nmol/L), tamoxifen (10 μ mol/L), and vehicle for 6 h. Whole cell lysates were immunoprecipitated with anti-HA. Immunoprecipitates by anti-Myc were subjected to immunoblotting with anti-Myc antibody (top) and anti-HA antibody (bottom). **B**, schematic representation of deletion mutants of HA-tagged HDAC6 and memER. **C**, ER α binds to HDAC6 through its activation function 2 domain. 293T cells were cotransfected with HDAC6-HA (full) and FLAG-tagged ER α deletion mutants. After 24-h incubation, cells were lysed and immunoprecipitated with anti-HA. Immunoprecipitates were immunoblotted with anti-FLAG (M5) antibody (top) and anti-HA antibody (bottom). **D**, HDAC6 binds to ER α with its deacetylase domain 2. 293T cells were cotransfected with memER and HA-tagged HDAC6 plasmids. After 24-h incubation, cells were lysed and immunoprecipitated with anti-HA. Immunoprecipitates were immunoblotted with anti-FLAG (M5) antibody (top) and anti-HA antibody (bottom).



structure (16). Although the direct effect of tubulin deacetylation is not evaluated in these reports, it is possible that deacetylated tubulin affects focal adhesion turnover and regulates anoikis resistance.

Because HDAC6 itself is reported as an estrogen-induced gene and HDAC6 overexpression is shown to enhance cell motility (8, 9), the estrogen-dependent up-regulation of HDAC6 could further potentiate its enzymatic activity. In this case, the genomic action of estrogen would promote its nongenomic action in MCF-7 cells. In contrast, the tamoxifen-induced nongenomic action would be unfavorable for the antagonistic function of this drug in the genomic action. We showed that tamoxifen also caused the interaction of memER with HDAC6 and tubulin deacetylation in MCF-7 cells. We assume that HDAC6-dependent tubulin deacetylation contributes to the increased cell motility and invasive migration of breast cancer cells; thus, this nongenomic action of the tamoxifen-induced tubulin deacetylation could be one of the reasons for tamoxifen resistance in breast cancer treatment. Indeed, several clinical trials have shown the superiority of aromatase inhibitors over tamoxifen in the first-line endocrine therapy for postmenopausal women with both early-stage and advanced breast cancers (17, 18). There is also a report that has shown tamoxifen-induced redistribution of ER α to the extranuclear region and the activation of nongenomic action via the epidermal growth factor receptor pathway (19), which would provide another mechanism for tamoxifen resistance.

HDAC6 also deacetylates another cytosolic protein, heat shock protein 90 (20). It has been shown that heat shock protein 90 could

be recruited to membrane ruffles, where deacetylated heat shock protein 90 promotes cell motility (21). As there is a recent report that ER α associates with deacetylated heat shock protein 90 in breast cancer cells (22), HDAC6-dependent estrogen action may also be mediated through the complex formation of ER α -HDAC6 with heat shock protein 90.

In conclusion, we have shown that estrogen exerts rapid actions including the formation of the ER α -HDAC6-tubulin complex at the plasma membrane and tubulin deacetylation. This nongenomic action of estrogen could contribute to the malignant character of breast cancer cells. These findings provide a new clue to understand the mechanisms underlying the pathophysiology of breast cancer and the resistance to endocrine therapy, and to develop new molecular targets for breast cancer treatment.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

Received 9/9/08; revised 1/6/09; accepted 1/9/09; published OnlineFirst 3/24/09.

Grant support: Genome Network Project and DECODE from the Ministry of Education, Culture, Sports, Science and Technology, Grants from the Japan Society for the Promotion of Science, and Grants-in-Aid from the Ministry of Health, Labor and Welfare.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Stuart L. Schreiber for providing HDAC6 cDNA and A. Okada for his technical assistance.

References

- Rabaglio M, Aebi S, Castiglione-Gertsch M. Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. *Lancet Oncol* 2007;8:940-9.
- Cheskis BJ, Greger JG, Nagpal S, Freedman LP. Signaling by estrogens. *J Cell Physiol* 2007;213:610-7.
- Simoncini T, Hafezi-Moghadam A, Brazil DP, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. *Nature* 2000;407:538-41.
- Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. *Cell* 2001;104:719-30.
- Migliaccio A, Di Domenico M, Castoria G, et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. *EMBO J* 1996;15:1292-300.
- Azuma K, Horie K, Inoue S, Ouchi Y, Sakai R. Analysis of estrogen receptor α signaling complex at the plasma membrane. *FEBS Lett* 2004;577:339-44.
- Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubule-associated deacetylase. *Nature* 2002;417:455-8.
- Yoshida N, Omoto Y, Inoue A, et al. Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. *Cancer Sci* 2004;95:496-502.
- Saji S, Kawakami M, Hayashi S, et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. *Oncogene* 2005;24:4531-9.
- Rai D, Frulova A, Frasier J, Carpenter AE, Katzenellenbogen BS. Distinctive actions of membrane-targeted versus nuclear localized estrogen receptors in breast cancer cells. *Mol Endocrinol* 2005;19:1606-17.
- Azuma K, Tanaka M, Uekita T, et al. Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma. *Oncogene* 2005;24:4754-64.
- Urano T, Saito T, Tsukui T, et al. Efp targets 14-3-3 σ for proteolysis and promotes breast tumour growth. *Nature* 2002;417:871-5.
- Tran AD, Marmo TP, Salam AA, et al. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. *J Cell Sci* 2007;120:1469-79.
- Reddig PJ, Juliano RL. Clinging to life: cell to matrix adhesion and cell survival. *Cancer Metastasis Rev* 2005;24:425-39.
- Lee YS, Lim KH, Guo X, et al. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. *Cancer Res* 2008;68:7561-9.
- Deschesnes RG, Patenaude A, Rousseau JL, et al. Microtubule-destabilizing agents induce focal adhesion structure disorganization and anoikis in cancer cells. *J Pharmacol Exp Ther* 2007;320:853-64.
- Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. *N Engl J Med* 2005;353:2747-57.
- Mouridsen H, Gershonovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. *J Clin Oncol* 2003;21:2101-9.
- Fan P, Wang J, Santen RJ, Yue W. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor α out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. *Cancer Res* 2007;67:1352-60.
- Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. *Mol Cell* 2005;18:601-7.
- Gao YS, Hubbert CC, Lu J, et al. Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. *Mol Cell Biol* 2007;27:8637-47.
- Fiskus W, Ren Y, Mohapatra A, et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor- α levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. *Clin Cancer Res* 2007;13:4882-90.

RET protein promotes non-adherent growth of NB-39-nu neuroblastoma cell line

Hitoyasu Futami and Ryuichi Sakai¹

Growth Factor Division, National Cancer Center Research Institute, 5-1-1, Tsukiji-1, Chuo-ku, Tokyo 104-0044, Japan

Received February 18, 2009/Revised January 30, 2009/Accepted February 11, 2009

The receptor tyrosine kinase RET is expressed in a number of neuroblastoma tissues and cell lines, but its role in neuroblastoma remains to be determined. In this study, we examined the roles of RET protein in neuroblastoma by the RNA interference technique using the NB-39-nu neuroblastoma cell line. NB-39-nu neuroblastoma cells show high expression and elevated tyrosine phosphorylation of RET, although short interfering RNA against RET (RET siRNA) did not significantly inhibit cell proliferation or suppression of basal levels of phosphorylation of extracellular regulated kinase (ERK)1/2 or protein kinase B (AKT). By the addition of glial cell line-derived neurotrophic factor (GDNF), both the expression and phosphorylation of RET and the phosphorylation of ERK1/2 and AKT were further increased, whereas cell proliferation was not stimulated under normal culture conditions. However, proliferation of cells cultured under non-adherent conditions was significantly increased by GDNF. The increased proliferation was suppressed by RET siRNA, which also caused inhibition of the phosphorylation of ERK1/2 and AKT. These results suggest that RET signaling plays an important role in GDNF-induced enhancement of non-adherent proliferation of NB-39-nu cells, which might contribute to the metastasis of neuroblastoma. (*Cancer Sci* 2009)G

RET is a receptor tyrosine kinase that is expressed in various neurons including central motor dopaminergic and noradrenergic neurons as well as peripheral enteric sensory and sympathetic neurons.^(1,2) The expression of RET has also been detected in the mesonephric duct and branching ureteric bud during embryogenesis of the kidney.^(1,2) It has been shown that RET is required for the development of the sympathetic, parasympathetic, and enteric nervous systems as well as the kidney and testis.^(1,3) Dysfunctions of RET, which are caused by mutations of the gene, lead to various neuroendocrine tumors or enteric disorders. Germline gain-of-function mutations of RET are responsible for the dominantly inherited cancer syndromes of multiple endocrine neoplasia types 2A and 2B and familial medullary thyroid carcinoma.⁽⁴⁻⁶⁾ In addition, somatic mutations or rearrangements of RET have also been found in sporadic medullary thyroid carcinoma and papillary thyroid carcinoma, respectively.⁽⁷⁻¹⁰⁾ Loss-of-function mutations in RET have been found in some cases of Hirschsprung's disease characterized by severe constipation and intestinal obstructions during childhood.^(11,12)

Neuroblastoma is the most common extracranial tumor in children and is derived from sympathoadrenal lineage of the neural crest in which RET is expressed.⁽¹³⁾ Although RET is expressed in most neuroblastoma tissues and cell lines and its overexpression has been reported in some cell lines,⁽¹⁴⁻¹⁷⁾ its role in molecular pathogenesis in neuroblastoma remains to be determined.

Glial cell line-derived neurotrophic factor (GDNF), a ligand of RET protein, was originally purified as a growth factor promoting survival of the embryonic dopaminergic neurons and exhibiting a potent trophic factor for spinal motor neurons and central noradrenergic neurons.⁽¹⁸⁻²⁰⁾ GDNF induces dimerization of RET in the form of multicomponents with a coreceptor GFR α -1 and triggers autophosphorylation of RET in its intracellular tyrosine kinase

domain. The phosphorylated tyrosines serve as docking sites for signaling molecules such as Shc, FRS2, IRS1/2 and Dok1/4/5.⁽²¹⁾ In neuroblastoma, it has been shown that extracellular regulated kinase (ERK), phosphoinositide 3-kinase/protein kinase B (AKT), c-Jun N-terminal kinase, and p38MAP pathways are activated mainly through tyrosine 1062,⁽²²⁾ but their biological effects have not been fully elucidated.

In this study, we investigated the biological role of RET in neuroblastoma using the NB-39-nu neuroblastoma cell line, which shows extremely high expression and elevated phosphorylation of RET, by suppression of RET protein expression using RNA interference (RNAi).

Materials and Methods

Cell line and culture. NB-39-nu, Nagai,⁽²³⁾ and YT-nu⁽²⁴⁾ were provided by the Carcinogenesis Division, National Cancer Center Research Institute (Tokyo, Japan). NB-1 and TNB-1 were obtained from the Human Science Research Resource Bank (Tokyo, Japan). SK-N-SH was obtained from Riken Cell Bank (Tsukuba, Japan) and TT was obtained from the American Type Culture Collection (Manassas, VA, USA). These cell lines were maintained in RPMI-1640 medium with 10% heat-inactivated fetal bovine serum, 100 units/mL penicillin, and 100 μ g/mL streptomycin at 37°C with 5% CO₂.

Short interfering RNA. Short interfering RNA against human RET (RET siRNA) was generated using a BLOCK-IT RNAi TOPO Transcription Kit and BLOCK-IT Complete Dicer RNAi Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. In the generation of RET siRNA, 805 bp from the second nucleotide of the initiation codon of human RET was chosen as the target sequence, and amplified by polymerase chain reaction using human RET cDNA and the primers, 5'-tgccgaagggcagctccgg-3' and 5'-cgatgctcctcgtctgata-3'. The control LacZ siRNA was made using an expression plasmid containing the *lacZ* gene and polymerase chain reaction primers attached in the kit. Transfection was carried out with Lipofectamine 2000 (Invitrogen).

Antibodies and reagents. AMAnti-ERK1/2 antibody, anti-phospho-ERK1/2 antibody (phospho-p44/p42 mitogen-activated protein kinase antibody), anti-AKT antibody, and anti-phospho-AKT (Ser473) antibody were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-RET (C-19) antibody and Chr-A (chromogranin-A) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti- α -tubulin (B-5-1-2) antibodies were purchased from Sigma (St. Louis, MO, USA). Anti-GAP-43 was purchased from Zymed Laboratories (San Francisco, CA, USA). Anti-phospho-RET antibody was produced by immunizing rats with a synthetic phospho-peptide corresponding to residues around Tyr1062 of a long form of human RET. Horseradish peroxidase-conjugated antimouse and anti-rabbit antibodies were purchased

¹To whom correspondence should be addressed. E-mail: rsakai@ncc.go.jp




Fig. 1. (a) Expression of RET in various neuroblastoma cell lines. Exponentially growing neuroblastoma cell lines NB-39-nu, Nagai, NB-1, YT-nu, SK-N-SH, TNB-1, and a medullary thyroid carcinoma TT were harvested and the cell lysates subjected to Western blot analysis. (b) RET knockdown does not affect extracellular regulated kinase (ERK)1/2 or protein kinase B (AKT) signaling pathways in NB-39-nu cells. NB-39-nu cells (10×10^4 /mL, 2 mL/well) were seeded in conventional 6-well plates in 10% fetal bovine serum containing RPMI-1640 medium, followed by treatment with LacZ short interfering RNA (siRNA) or RET siRNA at 0 h and 24 h, then harvested at 48 h for Western blot analysis. pAKT, phosphorylated AKT; pERK1/2, phosphorylated ERK1/2. (c, d) Glial cell line-derived neurotrophic factor (GDNF) enhances ERK1/2 and AKT signaling pathways in NB-39-nu cells in a RET-dependent manner. NB-39-nu cells (10×10^4 /mL, 2 mL/well) were seeded in conventional 6-well plates in 10% fetal bovine serum containing RPMI-1640 medium, followed by treatment with LacZ siRNA or RET siRNA at 0 h and 24 h. After the cells were harvested at 48 h, the adherent cells were cultured with GDNF (50 ng/mL) for 24 h in conventional 6-well plates (c), while the non-adherent cells were cultured in 2-methacryloxyethyl phosphorylcholine-treated 6-well plates (d). The treatment was terminated at 72 h by harvesting the cells for Western blot analysis.

from Amersham Pharmacia (Little Chalfont, UK). Human recombinant GDNF was purchased from Sigma.

Cell proliferation assay. Cell proliferation was analyzed by Tetra Color One (Seikagaku, Tokyo, Japan) according to the manufacturer's instructions. Briefly, 3×10^3 or 1×10^4 cells/well were seeded in normal or low-cell-binding 96-well plates treated with 2-methacryloxyethyl phosphorylcholine (MPC; Nalge Nunc International, Tokyo, Japan). The cells were cultured for 24 or 48 h with or without GDNF (50 ng/mL) then subjected to Tetra Color for 3 h, followed by measurement for proliferation. The absorbance of the samples was measured at 450 nm on a microplate reader model 550 (Bio-Rad, Hercules, CA, USA).

Western blot analysis. The cell lysates were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and transferred to a polyvinylidene difluoride membrane (Immobilon-P; Millipore, Bedford, MA, USA). After blocking of the membrane with blocking buffer (5% skim milk in TBST), the membrane was probed with antibodies for detection. The membrane was further probed with horseradish peroxidase-conjugated antirabbit or anti-mouse IgG to visualize the reacted antibody.

Results

Expression of RET in various neuroblastoma cell lines. We first estimated the levels of the expression and phosphorylation of RET in various neuroblastoma cell lines and compared the estimated levels with those of the TT medullary thyroid carcinoma cell line, which carries gain-of-function mutation of RET at C634W. Although RET was expressed in all six neuroblastoma cell lines, the levels of expression and phosphorylation of RET greatly varied among cell lines (Fig. 1a). Among the six neuroblastoma cell lines evaluated, two cell lines, NB-39-nu and Nagai, showed a high level of expression and phosphorylation of RET, which were comparable to or higher than those of TT.

GDNF enhances ERK1/2 and AKT signaling pathways in adherent NB-39-nu cells in a RET-dependent manner. We next knocked down RET expression to see the effect of activated RET signaling in NB-39-nu cells, one of the two neuroblastoma cell lines that showed a remarkable level of RET expression. As shown in Figure 1(b), RET expression was dramatically suppressed by treatment using RET RNAi, whereas phosphorylation of ERK1/2 and AKT, which




Fig. 2. Glial cell line-derived neurotrophic factor (GDNF) enhances the cell growth of non-adherent NB-39-nu cells but not of adherent cells. Cells (3×10^4 /mL, 2.5 mL/well) were seeded in conventional or 2-methacryloyloxyethyl phosphorycholine-treated 6-well plates, and cultured with GDNF (50 ng/mL) for 24, 48, 72, and 96 h. The cells were harvested by trypsinization at the indicated time points, then cell numbers were measured using a Coulter counter. Points, means of three replicates; bars, standard deviation.




Fig. 3. RET knockdown abrogates glial cell line-derived neurotrophic factor (GDNF)-stimulated proliferation of non-adherent NB-39-nu neuroblastoma cells. NB-39-nu cells (10×10^4 /mL, 2 mL/well) were seeded in conventional 6-well plates in 10% fetal bovine serum containing RPMI-1640 medium, followed by treatment with LacZ short interfering RNA (siRNA) or RET siRNA at 0 h and 24 h. At 48 h, the cells were harvested and seeded (3×10^4 /mL, 0.1 mL/well) in conventional or 2-methacryloyloxyethyl phosphorycholine-treated 96-well plates with or without GDNF (50 ng/mL) for 24 or 48 h. Cell proliferations were determined at the indicated time points by Tetra Color One assay as described in Materials and Methods. Columns, means of three replicates; bars, standard deviation.

have been reported to be universal downstream targets of receptor tyrosine kinases including RET, were not significantly affected. This suggests that these downstream signaling pathways are not under the regulation of activated RET under normal culture conditions. However, phosphorylation of ERK1/2 and AKT were significantly enhanced by GDNF treatment in the existence of serum, as indicated in Figure 1(c), and this enhancement was lost by the knockdown of RET protein, indicating that ERK1/2 and AKT signals were activated by the stimulation with GDNF in a RET-dependent manner in this cell line. Phosphorylation of AKT and ERK1/2 was also increased by stimulation of GDNF in the serum-depleted condition after serum starvation, and the increased phosphorylation of AKT was inhibited by RET knockdown, whereas that of ERK1/2 by RET knockdown was not obvious (Fig. S1).

GDNF enhances cell proliferation of non-adherent NB-39-nu cells but not of adherent cells. As RET downstream signaling was stimulated by the treatment of GDNF in NB-39-nu cells, we next examined the effect of GDNF on the proliferation of NB-39-nu cells. The

growth of the cells cultured under adherent conditions was not significantly changed by the treatment with GDNF (Fig. 2a), but the growth of the cells under non-adherent conditions was stimulated by the treatment with GDNF (Fig. 2b). In this study, we used the low attachment plate by Nunc (MPC plate as described in 'Materials and Methods').²⁵ In the MPC plate, almost all cells grew under non-adherent conditions, detached from the bottom of the plate (Fig. 2b, lower panels). The proliferation of NB-39-nu cells was also measured using Tetra Color One assay, as described in 'Materials and Methods', and it was confirmed that marked enhancement in the proliferation of the cells was specifically observed under non-adherent conditions by the treatment with GDNF (Fig. 3). In addition, RET knockdown inhibited GDNF-stimulated proliferation of NB-39-nu cells under non-adherent conditions, suggesting that GDNF promotes non-adherent proliferation of NB-39-nu cells in a RET-dependent manner (Fig. 3). At the same time, knockdown of RET protein under non-adherent conditions caused suppression of the amount of activated ERK1/2 and ATK (Fig. 1d).

In addition to NB-39-nu cells, another neuroblastoma cell line, NB-1, was evaluated for proliferation when treated with GDNF with or without RET-knockdown. Like NB-39-nu cells, the proliferation of NB-1 cells was enhanced by GDNF under non-adherent conditions, but not under adherent conditions, and the enhancement was inhibited by RET knockdown (Fig. S2).

GDNF does not induce neuronal differentiation markers in NB-39-nu cells. It has been shown that GDNF induces cell differentiation in most primary neuroblastoma tissues, which generally has an inhibitory effect on the proliferation of cancer cells, so we investigated whether differentiation was induced by GDNF treatment of NB-39-nu cells by monitoring two neuronal markers, GAP-43 and chromogranin-A. The treatment did not cause upregulation of these markers at a protein level, under either adherent or non-adherent conditions (Fig. 4a). In addition, no obvious morphological changes, such as neurite outgrowth, were observed with the addition of GDNF under adherent conditions (Fig. 4b, upper panels). These findings suggest that the treatment of GDNF did not induce neuronal differentiation under the experimental conditions. Furthermore, the cells showed evidence of cluster formations under non-adherent conditions, and the clusters of the cells treated with GDNF appeared to be significantly larger (Fig. 4b, lower panels).

Discussion

It has been shown that RET is expressed in most neuroblastoma cell lines and tissues, although its role in neuroblastoma remains to be determined. In this study, we analyzed the role of RET protein in neuroblastoma using NB-39-nu cells in which especially high levels of expression and tyrosine phosphorylation of RET




Fig. 4. GDNF does not induce neuronal differentiation markers or morphological changes in adherent NB-39-nu cells. NB-39-nu cells (10×10^4 /well, 2 ml/well) were seeded in conventional or 2-methacryloxyethyl phosphorylcholine-treated 6-well plates in 10% fetal bovine serum containing RPMI-1640 medium with or without glial cell line-derived neurotrophic factor (GDNF; 50 ng/ml) for 24 or 48 h. (a) The cells were harvested for Western blot analysis at 24 h and 48 h. (b) Microscopic appearance of NB-39-nu cells cultured with or without GDNF under adherent or non-adherent conditions at 48 h.

protein were observed. In two of the six cell lines examined, NB-39-nu and Nagai cells, the expression and phosphorylation levels of RET protein were comparable to or higher than those of TT cells. TT cells are derived from medullary thyroid carcinoma, and were found to harbor C634W gain-of-function mutation of RET. It was considered that activation of RET caused by gain-of-function mutation, which led to constitutive activation of downstream signaling, is responsible for oncogenesis in TT cells. Actually, it has been shown that the inhibition of RET signaling by expressing a dominant negative form of RET leads to suppression of ERK1/2 and AKT and the proliferation in TT cells, suggesting that the activated RET plays an important role in proliferation.^(26,27) Although RET protein shows high levels of tyrosine phosphorylation in NB-39-nu and Nagai cells without any known mutations, the proliferation and downstream signaling of RET were not inhibited by RET RNAi of NB-39-nu cells under normal culture conditions in this study.

However, ERK1/2 and AKT, downstream molecules of RET protein, were further activated upon the stimulation of its ligand, GDNF, in a RET-dependent manner, suggesting a ligand-dependent nature as a wild-type RET protein. Nevertheless, the proliferation of the cells under adherent conditions was not stimulated even by the treatment with GDNF. Interestingly, the proliferation of NB-39-nu cells was stimulated by GDNF treatment under non-adherent conditions, and this was suppressed by RET siRNA. These results suggest that GDNF promotes non-adherent proliferation of NB-39-nu cells in a RET-dependent manner. Similar results of the effect of GDNF on proliferation were observed in another neuroblastoma cell line, NB-1, suggesting that the phenomenon of RET-dependent GDNF-induced increase of proliferation under non-adherent conditions was not exclusive to NB-39-nu cells.

We noticed that RET knockdown had an obvious inhibitory effect on the activation of both ERK1/2 and AKT in long-term stimulation (24 h) by GDNF in the existence of serum, but it had little inhibitory effect on the activation of ERK1/2 in rapid stimulation (15 min) by GDNF after serum starvation, suggesting a special mechanism of long-term activation of ERK1/2 by GDNF-RET signaling.

When the NB-39-nu cells were cultured in non-adherent conditions, they grew in cluster formations, as shown in Figure 4(b).

It has been shown that intercellular adhesion under non-adherent conditions generates the stimulations that support survival and proliferation in some cell lines.^(28,29) GDNF might enhance this intercellular stimulation generated by cluster formation of the cells, resulting in promotion of the proliferation of the cells. In the metastasis cascade, it is considered to be a critical step that the metastasizing cancer cells become detached from the extracellular matrix and survive and proliferate only in touch with adjacent cancer cells, suggesting the possibility that GDNF-RET signaling might promote cancer metastasis by facilitating this step.^(30,31)

It has been shown that GDNF induces differentiation in most neuroblastoma tissues by the primary culture system.⁽¹⁷⁾ Therefore, we initially suspected that the loss of the growth promotion effect of GDNF under adherent conditions was due to its induction of differentiation. However, GDNF stimulation did not cause either induction of neuronal markers, such as GAP-43 and chromogranin-A, nor morphological changes such as neurite outgrowth, suggesting that neuronal differentiation was not induced by the treatment of GDNF in NB-39-nu cells under adherent conditions.

We previously established that anaplastic lymphoma kinase (ALK) was overexpressed and activated by gene amplification in NB-39-nu cells, and found that the AKT and ERK1/2 signals were significantly blocked by the knockdown of ALK,^(32,33) suggesting that activation of ALK dominates the growth and survival signaling in this cell line. Thus, it is possible that the growth of NB-39-nu cells under GDNF-free conditions, or under adherent conditions, is mainly sustained by activated ALK. This is also the case with NB-1 which overexpresses ALK. Furthermore, we observed that the proliferations in other neuroblastoma cell lines, TNB-1 and YT-nu, that do not have overexpressed ALK were enhanced by GDNF under both adherent and non-adherent conditions (data not shown), suggesting that the cell proliferation might be dominantly regulated by activated ALK which overcomes GDNF-RET signaling under adherent conditions in NB-39-nu and NB-1 cells. GDNF-RET signaling might have a special role in non-adherent growth that might not be supported by signals from other growth factor receptors, including ALK.

It was previously reported that the proliferation of SH-SY5Y neuroblastoma cell line was enhanced by GDNF with the

1 activation of the ERK1/2 and AKT signaling pathways under
2 conventional conditions.³⁴ Conversely, as we have shown, GDNF
3 did not stimulate the proliferation of NB-39-nu cells under adherent
4 conditions, but it did enhance the signaling pathway of ERK1/2
5 and AKT. Although the mechanism by which the differential ability
6 of GDNF to proliferate the cells between these two cell lines
7 remains to be elucidated, the dominant influence of the activated
8 ALK pathway in NB-39-nu cells is naturally suspected. It could
9 be postulated that other pathways such as the signal from NCAM,³⁵
10 also a receptor for GDNF, might contribute differently to the
11 signaling pathway for proliferation between these two cell lines
12 growing under adherent conditions.

13 Various neuroblastoma cell lines secrete GDNF under the con-
14 trols of various cytokines and growth factors that are also gener-

ated from neuroblastoma.^{17,36} Thus, the fact that GDNF promotes
the non-adherent growth of NB-39-nu neuroblastoma cells might
suggest that GDNF generated from neuroblastoma cells could
contribute to tumor growth, progression, and metastasis in an
autocrine and paracrine fashion, at least in some neuroblastoma.

Acknowledgments

This work was supported by a Grant-in Aid for Cancer Research by the
Ministry of Education, Culture, Sports, Science and Technology of Japan
and in part by a Grant-in-Aid from the Ministry of Health, Labor and
Welfare of Japan for the 3rd-term Comprehensive 10-year Strategy for
Cancer Control.

References

- 1 Pachnis V, Mankoo B, Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. *Development* 1993; **119**: 1005-17.
- 2 Tsuzuki T, Takahashi M, Asai N, Iwashita T, Matsuyama M, Asai J. Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. *Oncogene* 1995; **10**: 191-8.
- 3 Jain S, Naughton CK, Yang M *et al*. Mice expressing a dominant-negative Ret mutation phenocopy human Hirschsprung disease and delineate a direct role of Ret in spermatogenesis. *Development* 2004; **131**: 5503-13.
- 4 Donis KH, Dou S, Chi D *et al*. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. *Hum Mol Genet* 1993; **2**: 851-6.
- 5 Mulligan LM, Kwok JB, Healey CS *et al*. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. *Nature* 1993; **363**: 458-60.
- 6 Hofstra RM, Landsvater RM, Ceccherini I *et al*. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. (See comment in *Nature* 1994; **367**: 319-20.) *Nature* 1994; **367**: 375-6.
- 7 Eng C, Mulligan LM, Smith DP *et al*. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. *Genes Chromosomes Cancer* 1995; **12**: 209-12.
- 8 Eng C, Smith DP, Mulligan LM *et al*. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. *Oncogene* 1995; **10**: 509-13.
- 9 Grieco M, Santoro M, Berlingieri MT *et al*. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected *in vivo* in human thyroid papillary carcinomas. *Cell* 1990; **60**: 557-63.
- 10 Bongarzone I, Monzini N, Borrello MG *et al*. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit R1α of cyclic AMP-dependent protein kinase A. *Mol Cell Biol* 1993; **13**: 358-66.
- 11 Ederly P, Lyonnet S, Mulligan LM *et al*. Mutations of the RET proto-oncogene in Hirschsprung's disease. (See comment in *Nature* 1994; **367**: 319-20.) *Nature* 1994; **367**: 378-80.
- 12 Romeo G, Ronchetto P, Luo Y *et al*. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease (See comment in *Nature* 1994; **367**: 319-20.) *Nature* 1994; **367**: 377-8.
- 13 Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. *Nat Rev Cancer* 2003; **3**: 203-16.
- 14 Nagao M, Ishizaka Y, Nakagawara A *et al*. Expression of ret proto-oncogene in human neuroblastomas. *Jpn J Cancer Res* 1990; **81**: 309-12.
- 15 Ikeda I, Ishizaka Y, Tahira T *et al*. Specific expression of the ret proto-oncogene in human neuroblastoma cell lines. *Oncogene* 1990; **5**: 1291-6.
- 16 Borrello MG, Bongarzone I, Pierotti MA *et al*. trk and ret proto-oncogene expression in human neuroblastoma specimens: high frequency of trk expression in non-advanced stages. *Int J Cancer* 1993; **54**: 540-5.
- 17 Hishiki T, Nimura Y, Isogai E *et al*. Glial cell line-derived neurotrophic factor/neurturin-induced differentiation and its enhancement by retinoic acid in primary human neuroblastomas expressing c-Ret, GFRα-1, and GFRα-2. *Cancer Res* 1998; **58**: 2158-65.
- 18 Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-

- derived neurotrophic factor for midbrain dopaminergic neurons. *Science* 1993; **260**: 1130-2.
- 19 Henderson CE, Phillips HS, Pollock RA *et al*. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. *Science* 1994; **266**: 1062-4.
- 20 Arenas E, Trupp M, Akerud P, Ibanez CF. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons *in vivo*. *Neuron* 1995; **15**: 1465-73.
- 21 Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. *Cytokine Growth Factor Rev* 2005; **16**: 441-67.
- 22 Hayashi H, Ichihara M, Iwashita T *et al*. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. *Oncogene* 2000; **19**: 4469-75.
- 23 Ishikawa S, Ohshima Y, Suzuki T, Oboshi S. Primitive neuroectodermal tumor (neuroepithelioma) of spinal nerve root - Report of an adult case and establishment of a cell line. *Acta Pathol Jpn* 1979; **29**: 289-301.
- 24 Kuga N, Yoshida K, Seido T *et al*. Heterotransplantation of cultured human cancer cells and human cancer tissues into nude mice. *Gann* 1975; **66**: 547-60.
- 25 Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T, Sakai R. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. *Mol Cell Biol* 2007; **27**: 7649-60.
- 26 Drosten M, Stiewe T, Putzer BM. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. *Hum Gene Ther* 2003; **14**: 971-82.
- 27 Drosten M, Hilken G, Bockmann M *et al*. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. *J Natl Cancer Inst* 2004; **96**: 1231-9.
- 28 Bates RC, Edwards NS, Yates JD. Spheroids and cell survival. *Crit Rev Oncol Hematol* 2000; **36**: 61-74.
- 29 Lawlor ER, Scheel C, Irving J, Sorensen PH. Anchorage-independent multicellular spheroids as an *in vitro* model of growth signaling in Ewing tumors. *Oncogene* 2002; **21**: 307-18.
- 30 Volk T, Geiger B, Raz A. Motility and adhesive properties of high- and low-metastatic murine neoplastic cells. *Cancer Res* 1984; **44**: 811-24.
- 31 Nabi IR, Raz A. Loss of metastatic responsiveness to cell shape modulation in a newly characterized B16 melanoma adhesive cell variant. *Cancer Res* 1988; **48**: 1258-64.
- 32 Miyake I, Hakomori Y, Mitsu Y *et al*. Domain-specific function of ShcC docking protein in neuroblastoma cells. *Oncogene* 2005; **24**: 3206-15.
- 33 Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R. Biological role of anaplastic lymphoma kinase in neuroblastoma. *Am J Pathol* 2005; **167**: 213-22.
- 34 Hirata Y, Kiuchi K. Mitogenic effect of glial cell line-derived neurotrophic factor is dependent on the activation of p70S6 kinase, but independent of the activation of ERK and up-regulation of Ret in SH-SY5Y cells. *Brain Res* 2003; **983**: 1-12.
- 35 Paratcha G, Ledda F, Ibanez CF. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. *Cell* 2003; **113**: 867-79.
- 36 Verity AN, Wyatt TL, Lee W *et al*. Differential regulation of glial cell line-derived neurotrophic factor (GDNF) expression in human neuroblastoma and glioblastoma cell lines. *J Neurosci Res* 1999; **55**: 187-97.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Fig. S1. Glial cell line-derived neurotrophic factor (GDNF)-induced enhancement of extracellular regulated kinase (ERK)1/2 and protein kinase B (AKT) signaling in serum-depleted conditionS in NB-39-nu neuroblastoma cells. NB-39-nu cells (10×10^4 /mL, 2 mL/well) were seeded in

1 conventional 6-well plates in 10% fetal bovine serum containing RPMI-1640 medium, followed by treatment with LacZ short interfering RNA
2 (siRNA) or RET siRNA at 0 h and 24 h, then harvested at 48 h. After culturing the cells in serum-depleted condition for 24 h under adherent con-
3 ditions, the cells were treated with GDNF (50 ng/mL) in serum-depleted conditions for 15 min, then harvested for Western blot analysis.

4
5 **Fig. S2.** RET knockdown abrogates glial cell line-derived neurotrophic factor (GDNF)-stimulated proliferation of non-adherent NB-1 neuroblastoma
6 cells. NB-1 cells (10×10^4 /mL, 2 mL/well) were seeded in conventional 6-well plates in 10% fetal bovine serum containing RPMI-1640 medium,
7 followed by treatment with LacZ short interfering RNA (siRNA) or RET siRNA at 0 h and 24 h. At the 48 h time point, the cells were harvested
8 and seeded (1×10^4 /mL, 0.1 mL/well) in conventional or 2-methacryloxyethyl phosphorylcholine-treated 96-well plates in 10% fetal bovine serum
9 containing RPMI-1640 medium with or without GDNF (50 ng/mL) for 24 or 48 h. RET knockdown was confirmed for the cells harvested at 48 h
10 by Western blot analysis. Cell proliferations were determined at the indicated time points by Tetra Color One assay as described in Materials and
11 Methods. Columns, means of three replicates; bars, standard deviation.

12 Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries
13 (other than missing material) should be directed to the corresponding author for the article.